ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Financial Statements and Exhibits

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Financial Statements and Exhibits
Item 9.01.

Story continues below

Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Press release dated August 28, 2017


Anthera Pharmaceuticals Inc Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1   Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy   · Trend toward preservation of renal function (eGFR) in blisibimod treated patients · Lack of disease progression,…
To view the full exhibit click here

About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

An ad to help with our costs